The week in pharma: action, reaction and insight – week to March 4, 2022

tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell. Editor

India’s Biocon announced a $3.3 billion deal to acquire the recently set up generics powerhouse Viatris’ biosimilars assets. US pharma giant Pfizer became the latest to hit a roadblock in its attempts to develop a Clostridioides difficile vaccine, (PF-06425090), reporting mixed results from a Phase III trial. Meantime, AstraZeneca and Sanofi presented positive new Phase III data on their RSV disease candidate nirsevimab last Wednesday. Also, drug developer Karyopharm suffered a setback with its endometrial p53 wild-type candidate Xpovio (selinexor).

Another biosimilars retreat, this time from Viatris

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical